Viridian Therapeutics, Inc. (0K1R.L)
USD 19.62
(-7.91%)
USD 19.62
(-7.91%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 48.4 Million USD | 20.92% |
| 2022 | 40.02 Million USD | 150.28% |
| 2021 | 15.99 Million USD | 42.57% |
| 2020 | 11.21 Million USD | -22.68% |
| 2019 | 14.5 Million USD | -1.99% |
| 2018 | 14.8 Million USD | 5.96% |
| 2017 | 13.97 Million USD | 204.71% |
| 2016 | 4.58 Million USD | 83.99% |
| 2015 | 2.49 Million USD | 18.78% |
| 2014 | 2.09 Million USD | 27.45% |
| 2013 | 1.64 Million USD | -93.2% |
| 2012 | 24.22 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 47.85 Million USD | -1.14% |
| 2024 Q2 | 56.32 Million USD | 17.71% |
| 2023 Q2 | 35.61 Million USD | -1.34% |
| 2023 Q3 | 45.18 Million USD | 26.88% |
| 2023 Q4 | 48.4 Million USD | 7.13% |
| 2023 FY | 48.4 Million USD | 20.92% |
| 2023 Q1 | 36.09 Million USD | -9.83% |
| 2022 Q1 | 16.52 Million USD | 3.31% |
| 2022 Q3 | 31.57 Million USD | 13.1% |
| 2022 Q2 | 27.91 Million USD | 68.95% |
| 2022 Q4 | 40.02 Million USD | 26.78% |
| 2022 FY | 40.02 Million USD | 150.28% |
| 2021 Q1 | 16.83 Million USD | 50.06% |
| 2021 Q3 | 16.61 Million USD | -13.87% |
| 2021 Q4 | 15.99 Million USD | -3.74% |
| 2021 FY | 15.99 Million USD | 42.57% |
| 2021 Q2 | 19.29 Million USD | 14.59% |
| 2020 Q1 | 12.05 Million USD | -16.94% |
| 2020 Q2 | 12.31 Million USD | 2.19% |
| 2020 FY | 11.21 Million USD | -22.68% |
| 2020 Q4 | 11.21 Million USD | -4.86% |
| 2020 Q3 | 11.79 Million USD | -4.25% |
| 2019 Q2 | 15.34 Million USD | 9.65% |
| 2019 FY | 14.5 Million USD | -1.99% |
| 2019 Q4 | 14.5 Million USD | -7.26% |
| 2019 Q3 | 15.64 Million USD | 1.95% |
| 2019 Q1 | 13.99 Million USD | -5.47% |
| 2018 FY | 14.8 Million USD | 5.96% |
| 2018 Q1 | 14.28 Million USD | 2.25% |
| 2018 Q3 | 15.83 Million USD | 11.39% |
| 2018 Q4 | 14.8 Million USD | -6.52% |
| 2018 Q2 | 14.21 Million USD | -0.49% |
| 2017 Q1 | 9.8 Million USD | 113.74% |
| 2017 FY | 13.97 Million USD | 204.71% |
| 2017 Q4 | 13.97 Million USD | 72.57% |
| 2017 Q3 | 8.09 Million USD | -6.84% |
| 2017 Q2 | 8.69 Million USD | -11.33% |
| 2016 Q3 | 2.85 Million USD | 9.6% |
| 2016 Q4 | 4.58 Million USD | 60.6% |
| 2016 Q2 | 2.6 Million USD | 6.02% |
| 2016 Q1 | 2.45 Million USD | -1.4% |
| 2016 FY | 4.58 Million USD | 83.99% |
| 2015 Q4 | 2.49 Million USD | 15.16% |
| 2015 Q1 | 2.59 Million USD | 23.83% |
| 2015 FY | 2.49 Million USD | 18.78% |
| 2015 Q3 | 2.16 Million USD | 0.6% |
| 2015 Q2 | 2.15 Million USD | -17.21% |
| 2014 Q4 | 2.09 Million USD | 5.16% |
| 2014 Q1 | 1.86 Million USD | 13.59% |
| 2014 Q2 | 2.19 Million USD | 17.64% |
| 2014 Q3 | 1.99 Million USD | -9.31% |
| 2014 FY | 2.09 Million USD | 27.45% |
| 2013 Q4 | 1.64 Million USD | 0.0% |
| 2013 FY | 1.64 Million USD | -93.2% |
| 2012 FY | 24.22 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Xeris Biopharma Holdings, Inc. | 347.58 Million USD | 86.075% |
| Arrowhead Pharmaceuticals, Inc. | 478.39 Million USD | 89.882% |
| Codexis, Inc. | 49.94 Million USD | 3.091% |
| Organovo Holdings, Inc. | 2.74 Million USD | -1661.354% |